13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CO39303

    Acronym: 

    CO39303

    ACTRN/NCT /ethics: 

    NCT03072238

    Scientific title: 

    A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III Tumour Stream Prostate
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Male Anticipated Start Date 2017-06-30
    Molecular Target Anticipated End Date 2023-09-09
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Male
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2017-06-30
    Anticipated End Date 2023-09-09

    Trial Summary

    The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

    Lay Summary

    A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting